Synergistic Increase of Serum BDNF in Alzheimer Patients Treated with Cerebrolysin and Donepezil: Association with Cognitive Improvement in ApoE4 Cases.

Alvarez XA, Alvarez I, Iglesias O, Crespo I, Figueroa J, Aleixandre M, Linares C, Granizo E, Garcia-Fantini M, Marey J, Masliah E, Winter S, Muresanu D, Moessler H

The international journal of neuropsychopharmacology7 Apr 2016Cited by 28 (Europe PMC)

PMID27207906PMCIDPMC4926802DOI10.1093/ijnp/pyw024PepBankPUB-27207906

Read at source PubMedAsk about this study

Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study6

2 results from studies that gave the peptide. 2 results from people.

01HumanNon-randomized trialMechanism
In mild-to-moderate Alzheimer patients, Cerebrolysin increased serum BDNF at week 16.
In plain wordsIn patients with Alzheimer disease, Cerebrolysin increased serum BDNF at week 16.
Peptide
Cerebrolysin
Outcome
IncreaseSerum BDNF at week 16
Study
n: not reported in source
Outcome group
Neuroprotection · Nervous system and cognition
Studied dose
Dose not stated
Source sentences
Summary
Cerebrolysin, but not donepezil, increased serum brain derived neurotrophic factor at week 16, while the combination therapy enhanced it at both week 16 and study endpoint.
1 context sentence(design, population, supporting numbers)
Summary · context
We evaluated the effects of Cerebrolysin, donepezil, and the combined therapy on brain derived neurotrophic factor serum levels at week 16 (end of Cerebrolysin treatment) and week 28 (endpoint) in mild-to-moderate Alzheimer's disease patients.
Report a problemFND-2720790601
02HumanNon-randomized trialMechanism
In Alzheimer patients, adding Cerebrolysin to donepezil produced higher BDNF responses than donepezil alone at week 16.
In plain wordsIn patients with Alzheimer disease, Cerebrolysin with donepezil increased BDNF responses more than donepezil alone at week 16.
Peptide
Cerebrolysin
Outcome
IncreaseCombination BDNF response versus donepezil at week 16
Study
n: not reported in source
Comparator
Donepezil alone
Outcome group
Neuroprotection · Nervous system and cognition
Studied dose
Dose not stated
Source sentences
Summary
Brain derived neurotrophic factor responses were significantly higher in the combination therapy group than in donepezil and Cerebrolysin groups at week 16 and week 28, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
We evaluated the effects of Cerebrolysin, donepezil, and the combined therapy on brain derived neurotrophic factor serum levels at week 16 (end of Cerebrolysin treatment) and week 28 (endpoint) in mild-to-moderate Alzheimer's disease patients.
Report a problemFND-2720790604

Studies that did not test the peptide alone4

In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Cerebrolysin.

03HumanNot a test of Cerebrolysin aloneNon-randomized trialMechanism
In Alzheimer patients, combined Cerebrolysin and donepezil increased serum BDNF at week 16.
In plain wordsIn patients with Alzheimer disease, Cerebrolysin with donepezil increased serum BDNF at week 16.
Peptide
Cerebrolysin
Outcome
IncreaseCombination serum BDNF at week 16
Study
n: not reported in source
Outcome group
Neuroprotection · Nervous system and cognition
Source sentences
Summary
Cerebrolysin, but not donepezil, increased serum brain derived neurotrophic factor at week 16, while the combination therapy enhanced it at both week 16 and study endpoint.
1 context sentence(design, population, supporting numbers)
Summary · context
We evaluated the effects of Cerebrolysin, donepezil, and the combined therapy on brain derived neurotrophic factor serum levels at week 16 (end of Cerebrolysin treatment) and week 28 (endpoint) in mild-to-moderate Alzheimer's disease patients.
In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.
Report a problemFND-2720790602
04HumanNot a test of Cerebrolysin aloneNon-randomized trialMechanism
In Alzheimer patients, combined Cerebrolysin and donepezil increased serum BDNF at study endpoint, week 28.
In plain wordsIn patients with Alzheimer disease, Cerebrolysin with donepezil increased serum BDNF at week 28.
Peptide
Cerebrolysin
Outcome
IncreaseCombination serum BDNF at week 28
Study
n: not reported in source
Outcome group
Neuroprotection · Nervous system and cognition
Source sentences
Summary
Cerebrolysin, but not donepezil, increased serum brain derived neurotrophic factor at week 16, while the combination therapy enhanced it at both week 16 and study endpoint.
1 context sentence(design, population, supporting numbers)
Summary · context
We evaluated the effects of Cerebrolysin, donepezil, and the combined therapy on brain derived neurotrophic factor serum levels at week 16 (end of Cerebrolysin treatment) and week 28 (endpoint) in mild-to-moderate Alzheimer's disease patients.
In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.
Report a problemFND-2720790603
05HumanNot a test of Cerebrolysin aloneNon-randomized trialMechanism
In Alzheimer patients, Cerebrolysin with donepezil produced higher BDNF responses than Cerebrolysin alone at week 28.
In plain wordsIn patients with Alzheimer disease, Cerebrolysin with donepezil increased BDNF responses more than Cerebrolysin alone at week 28.
Peptide
Cerebrolysin
Outcome
IncreaseCombination BDNF response versus Cerebrolysin at week 28
Study
n: not reported in source
Comparator
Cerebrolysin alone
Outcome group
Neuroprotection · Nervous system and cognition
Source sentences
Summary
Brain derived neurotrophic factor responses were significantly higher in the combination therapy group than in donepezil and Cerebrolysin groups at week 16 and week 28, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
We evaluated the effects of Cerebrolysin, donepezil, and the combined therapy on brain derived neurotrophic factor serum levels at week 16 (end of Cerebrolysin treatment) and week 28 (endpoint) in mild-to-moderate Alzheimer's disease patients.
In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.
Report a problemFND-2720790605
06HumanNot a test of Cerebrolysin aloneNon-randomized trialOther
In Alzheimer patients with the apolipoprotein E epsilon-4 allele treated with Cerebrolysin or the combined therapy with donepezil, higher BDNF levels were associated with better cognitive improvements.
In plain wordsIn Alzheimer patients with the ApoE4 variant given Cerebrolysin or Cerebrolysin with donepezil, higher BDNF levels were linked to better cognitive improvement.
Peptide
Cerebrolysin
Outcome
Not applicableBDNF association with cognitive improvement
Study
n: not reported in source
Outcome group
Cognition and memory · Nervous system and cognition
Source sentences
Summary
and higher brain derived neurotrophic factor levels were associated with better cognitive improvements in apolipoprotein E epsilon-4 allele patients treated with Cerebrolysin and the combined therapy.
1 context sentence(design, population, supporting numbers)
Summary · context
We evaluated the effects of Cerebrolysin, donepezil, and the combined therapy on brain derived neurotrophic factor serum levels at week 16 (end of Cerebrolysin treatment) and week 28 (endpoint) in mild-to-moderate Alzheimer's disease patients.
In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.
Report a problemFND-2720790607

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.